In summary, our study confirms that PUS1 interacts with EIF3b, suppressing TTC3-mediated ubiquitination degradation, thereby identifying PUS1 as a novel protective molecule of EIF3b, mediating prostate cancer metastasis both in vitro and in vivo. Here, PUS1 is linked to prostate carcinoma.